Successful treatment with convalescent plasma in Covid-19 disease in relaps/refractory multiple myeloma

Authors

  • Ahmet Sarici Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Soykan Bicim Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Mehmet Ali Erkurt Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Ilhami Berber Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Emin Kaya Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Irfan Kuku Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey
  • Mustafa Ozgul Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey

Keywords:

Comorbidity, Convalescent plasma, immunocompromised patient, multiple myeloma, SARS-CoV-2 infection

Abstract

The Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus detected in the Wuhan Province of the People's Republic of China caused a pandemic in a very short time all over the world. Convalescent plasma (CP) therapy is a passive antibody therapy that has been shown to be effective in epidemic periods. CP therapy has been of interest in the treatment of infection with no vaccine or specific treatment, such as the Sars-CoV-2 infection that causes COVID-19. We aimed to report our CP experience in Sars-Cov-2 infection in our relapsed / refractory Multiple myeloma (MM) patient.

Downloads

Download data is not yet available.

Downloads

Published

2021-12-23

How to Cite

Sarici, A., Bicim, S., Erkurt, M. A., Berber, I., Kaya, E., Kuku, I., & Ozgul, M. (2021). Successful treatment with convalescent plasma in Covid-19 disease in relaps/refractory multiple myeloma. Annals of Medical Research, 28(12), 2239–2241. Retrieved from https://annalsmedres.org/index.php/aomr/article/view/4008

Issue

Section

Case Reports

Most read articles by the same author(s)

1 2 3 > >>